+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07440537

A Phase II Randomized, Double-Blind Study of Oral ICP-488 for Treating Cutaneous Lupus Erythematosus CLE

Led by Beijing InnoCare Pharma Tech Co., Ltd. · Updated on 2026-06-08

105

Participants Needed

27

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of the oral drug ICP-488 in adults with cutaneous lupus erythematosus CLE, a condition affecting the skin. This is a Phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to compare ICP-488 with a placebo in people aged 18 to 75 years who have had CLE for at least three months. The study is sponsored by Beijing InnoCare Pharma Tech Co., Ltd. Participants will receive either one of two doses of ICP-488 tablets or a matching placebo orally, according to the study protocol. The trial includes a 16-week treatment period during which researchers will assess changes in skin disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity CLASI-A. Treatment effects and safety will be monitored up to week 28, including evaluations of adverse events, laboratory tests, electrocardiograms, and vital signs. During the study, participants will undergo regular assessments of their skin condition using CLASI-A scores at multiple visits. Researchers will also monitor drug levels in the blood up to week 12. The primary outcome is the percentage change in CLASI-A at week 16 compared to baseline. Secondary outcomes include various measures of skin improvement and safety over 28 weeks. Participants are expected to maintain stable background treatments throughout the study, and women of childbearing potential and male participants must use effective contraception during and for 28 days after treatment.

CONDITIONS

Brief Title

Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

Research Team

A

Alexia Lu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here